Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. 2009

Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan.

BACKGROUND Cognitive deficits, including memory impairment, are regarded as a core feature of schizophrenia. Aripiprazole, an atypical antipsychotic drug, has been shown to improve disruption of prepulse inhibition and social interaction in an animal model of schizophrenia induced by phencyclidine (PCP); however, the effects of aripiprazole on recognition memory remain to be investigated. OBJECTIVE In this study, we examined the effect of aripiprazole on cognitive impairment in mice treated with PCP repeatedly. METHODS Mice were repeatedly administered PCP at a dose of 10 mg/kg for 14 days, and their cognitive function was assessed using a novel-object recognition task. We investigated the therapeutic effects of aripiprazole (0.01-1.0 mg/kg) and haloperidol (0.3 and 1.0 mg/kg) on cognitive impairment in mice treated with PCP repeatedly. RESULTS Single (1.0 mg/kg) and repeated (0.03 and 0.1 mg/kg, for 7 days) treatment with aripiprazole ameliorated PCP-induced impairment of recognition memory, although single treatment significantly decreased the total exploration time during the training session. In contrast, both single and repeated treatment with haloperidol (0.3 and 1.0 mg/kg) failed to attenuate PCP-induced cognitive impairment. The ameliorating effect of aripiprazole on recognition memory in PCP-treated mice was blocked by co-treatment with a dopamine D1 receptor antagonist, SCH23390, and a serotonin 5-HT1A receptor antagonist, WAY100635; however, co-treatment with a D2 receptor antagonist raclopride had no effect on the ameliorating effect of aripiprazole. CONCLUSIONS These results suggest that the ameliorative effect of aripiprazole on PCP-induced memory impairment is associated with dopamine D1 and serotonin 5-HT1A receptors.

UI MeSH Term Description Entries
D008297 Male Males
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D010622 Phencyclidine A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust. 1-(1-Phenylcyclohexyl)piperidine,Angel Dust,CL-395,GP-121,Phencyclidine Hydrobromide,Phencyclidine Hydrochloride,Sernyl,Serylan,CL 395,CL395,Dust, Angel,GP 121,GP121
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D005106 Exploratory Behavior The tendency to explore or investigate a novel environment. It is considered a motivation not clearly distinguishable from curiosity. Curiosity,Novelty-Seeking Behavior,Behavior, Exploratory,Behavior, Novelty-Seeking,Behaviors, Exploratory,Behaviors, Novelty-Seeking,Curiosities,Exploratory Behaviors,Novelty Seeking Behavior,Novelty-Seeking Behaviors
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D000068180 Aripiprazole A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression. 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone,Abilify,Aripiprazol,OPC 14597,OPC-14597
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
February 2012, Neuropharmacology,
Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
October 2015, European journal of pharmacology,
Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
May 2014, The international journal of neuropsychopharmacology,
Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
September 2014, Pharmacology, biochemistry, and behavior,
Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
January 2021, Frontiers in psychiatry,
Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
November 2013, Scientific reports,
Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
August 2013, Psychopharmacology,
Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
April 2019, Behavioural brain research,
Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
May 2003, British journal of pharmacology,
Taku Nagai, and Rina Murai, and Kanae Matsui, and Hiroyuki Kamei, and Yukihiro Noda, and Hiroshi Furukawa, and Toshitaka Nabeshima
May 2012, Psychopharmacology,
Copied contents to your clipboard!